Emmanuel Eric Pazo

← Publications

Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome

Jiayan Chen, Guanghao Qin, Liangzhe Li, Yifan Qi, Huixin Che, He Huang, Yang Xia, Qing Zhang, Yi Wu, Lanting Yang, Salissou Moutari, Jonathan Edward Moore, Ling Xu, Wei He, Sile Yu, Emmanuel Eric Pazo, Xingru He

BMJ Open, 2023 · article · doi:10.1136/bmjopen-2023-073055 · cited by 4 · Open access (CC BY-NC)

Ocular surface & dry eye

Abstract

INTRODUCTION: Evaporative dry eye (EDE) is common and can lead to ocular pain, decreased visual quality and reduced quality of life. Intense pulsed light (IPL) and 3% diquafosol ophthalmic solution have been found to be beneficial in reducing signs and symptoms of dry eye. METHODS AND ANALYSIS: A randomised clinical trial will be performed at He Eye Specialist Hospital in Shenyang. 360 dry eye disease patients will be equally divided randomly into the IPL group, DQS group (3% diquafosol ophthalmic solution eye-drops) and IPL+group (IPL combined with 3% diquafosol eye-drops). All groups will be followed up for 4 weeks. The primary outcome measures will be the non-invasive tear break-up time and the Ocular Surface Disease Index change from the baseline. The secondary outcome measures willincludeconjunctival and cornea staining with fluorescein and lissamine, meibomian gland function and secretion quality, tear film lipid layer score, tear meniscus height, conjunctival hyperemia (redness score) changes . Adverse events also will be monitored and documented. DISCUSSION: This study aimed to assess whether the combination of IPL with 3% diquafosol ophthalmic solution (study group), IPL+ (study group), is more effective than IPL (active control group) or DQS (active control group) in participants with EDE. ETHICS AND DISSEMINATION: Management of dry eye with IPL combined with 3% diquafosol ophthalmic solution, registered on 23 January 2023. Ethics approval number: IRB (2022) K029.01. The study's findings will be shared regardless of the effect's direction. TRIAL REGISTRATION NUMBER: NCT05694026.

Keywords: dry eye; evaporative dry eye; intense pulsed light; diquafosol; eye drops; combination therapy; tear film break-up time; Ocular Surface Disease Index

Access

How to cite

Chen, J., Qin, G., Li, L., Qi, Y., Che, H., Huang, H., Xia, Y., Zhang, Q., Wu, Y., Yang, L., Moutari, S., Moore, J. E., Xu, L., He, W., Yu, S., Pazo, E. E., He, X. (2023). Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome. BMJ Open. https://doi.org/10.1136/bmjopen-2023-073055

@article{chen2023protocol,
  title = {{Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome}},
  author = {Chen, Jiayan and Qin, Guanghao and Li, Liangzhe and Qi, Yifan and Che, Huixin and Huang, He and Xia, Yang and Zhang, Qing and Wu, Yi and Yang, Lanting and Moutari, Salissou and Moore, Jonathan Edward and Xu, Ling and He, Wei and Yu, Sile and Pazo, Emmanuel Eric and He, Xingru},
  journal = {BMJ Open},
  year = {2023},
  doi = {10.1136/bmjopen-2023-073055},
  url = {https://doi.org/10.1136/bmjopen-2023-073055},
}

Related work